Immunovant, Inc.

Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage immunology company that completed its public listing in December 2019 through a business combination with Health Sciences Acquisitions Corporation 2, a blank-check vehicle sponsored by Health Sciences Acquisitions, LLC, an affiliate of Perceptive Advisors. The SPAC conducted its initial public offering in 2018 and was focused on the healthcare and life sciences sector. The Form 8-K filed December 20, 2019 reflects a material corporate event disclosure tied to the de-SPAC transaction, which brought Immunovant's FcRn-inhibitor antibody pipeline into the public markets under its current ticker. For complete filing history, sponsor intelligence, and SPAC deal analytics, sign up for full data access at SpacDesk.